Innovation in Pharmaceuticals: Adenovirus-based medicinal compositions
Powered by
Gain invaluable insights that can revolutionize your business
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating or maturing. This report specifically looks at innovation in Adenovirus-based medicinal compositions for the pharmaceuticals industry and the leading companies, start-ups and adoption trends. These insights help in making informed strategic decisions for a more durable source of competitive advantage
Innovation S-curve for Pharmaceuticals industry
Scope
Decode the key disruptive innovations impacting the pharmaceuticals sector, with specific focus on Adenovirus-based medicinal compositions and its trends in patent filing, identifying the leading companies and start-ups (and those with unicorn potential), key application areas plus examples from real-world scenarios and leading countries driving the innovation. In addition, we gauge the adoption trends in Adenovirus-based medicinal compositions, by analyzing funding/investing trends, demand for human capital/jobs, social media buzz, company filings, and the latest news in the area
Key Highlights
Adenovirus-based medicinal compositions: innovation landscape, patent filings trend, leading countries innovating, key application areas, top innovators, potential unicorns, real-world innovations, alternative dataset to track adoption trends using deals, jobs, social media, company filings, latest news, plus deep dive on key companies in Adenovirus-based medicinal compositions
Reasons to Buy
• Identify emerging, accelerating, and maturing innovations in the sector likely to be disruptive in the future
• Evaluate key companies at the forefront of these innovations and their disruptive impact
• Discover key start-ups innovating in the area and uncover those with unicorn potential
• Build strategic technology / product roadmaps to stay ahead of disruption through actionable intelligence
Targovax ASA
Vascular Biogenics Ltd
EpicentRx Inc
DNAtrix Inc
Genemedicine Ltd
Johnson & Johnson
Hangzhou Converd Co Ltd
Institut Catala d'Oncologia
CG Oncology Inc
Valo Therapeutics Oy
BioLineRx Ltd
Bayer AG
TILT Biotherapeutics Ltd
Ixogen Ltd
Beijing Bio-Targeting Therapeutics Technology Inc
Mayo Clinic
Momotaro-Gene Inc
Merck & Co Inc
Memorial Sloan Kettering Cancer Center
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.